163 related articles for article (PubMed ID: 10815930)
21. Active drug targeting with immunoconjugates to choroidal neovascularization.
Yasukawa T; Kimura H; Tabata Y; Miyamoto H; Honda Y; Ikada Y; Ogura Y
Curr Eye Res; 2000 Dec; 21(6):952-61. PubMed ID: 11262619
[TBL] [Abstract][Full Text] [Related]
22. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
She X; Matsuno F; Harada N; Tsai H; Seon BK
Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(3A):1485-500. PubMed ID: 9673360
[TBL] [Abstract][Full Text] [Related]
24. Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation.
Postiglione L; Di Domenico G; Caraglia M; Marra M; Giuberti G; Del Vecchio L; Montagnani S; Macri M; Bruno EM; Abbruzzese A; Rossi G
Int J Oncol; 2005 May; 26(5):1193-201. PubMed ID: 15809709
[TBL] [Abstract][Full Text] [Related]
25. mRNA expression of the angiogenesis markers VEGF and CD105 (endoglin) in human breast cancer.
Gómez-Esquer F; Agudo D; Martínez-Arribas F; Nuñez-Villar MJ; Schneider J
Anticancer Res; 2004; 24(3a):1581-5. PubMed ID: 15274325
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis and metastasis marker of human tumors.
Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
[TBL] [Abstract][Full Text] [Related]
27. CD105/smooth muscle actin double immunostaining discriminate between immature and mature tumor blood vessels.
Cîmpean AM; Raica M; Suciu C
Rom J Morphol Embryol; 2007; 48(1):41-5. PubMed ID: 17502949
[TBL] [Abstract][Full Text] [Related]
28. Expression of endoglin (CD105) in tumor blood vessels.
Seon BK
Int J Cancer; 2002 May; 99(2):310-1; author reply 312. PubMed ID: 11979450
[No Abstract] [Full Text] [Related]
29. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours.
Fonsatti E; Nicolay HJ; Altomonte M; Covre A; Maio M
Cardiovasc Res; 2010 Apr; 86(1):12-9. PubMed ID: 19812043
[TBL] [Abstract][Full Text] [Related]
30. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer.
Wikström P; Lissbrant IF; Stattin P; Egevad L; Bergh A
Prostate; 2002 Jun; 51(4):268-75. PubMed ID: 11987155
[TBL] [Abstract][Full Text] [Related]
31. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(5A):3621-8. PubMed ID: 9858949
[TBL] [Abstract][Full Text] [Related]
32. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
Tsujie M; Uneda S; Tsai H; Seon BK
Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
[TBL] [Abstract][Full Text] [Related]
33. Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells.
Wang JM; Kumar S; van Agthoven A; Kumar P; Pye D; Hunter RD
Int J Cancer; 1995 Sep; 62(6):791-6. PubMed ID: 7558432
[TBL] [Abstract][Full Text] [Related]
34. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis.
Kumar S; Ghellal A; Li C; Byrne G; Haboubi N; Wang JM; Bundred N
Cancer Res; 1999 Feb; 59(4):856-61. PubMed ID: 10029075
[TBL] [Abstract][Full Text] [Related]
35. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.
Fonsatti E; Sigalotti L; Arslan P; Altomonte M; Maio M
Curr Cancer Drug Targets; 2003 Dec; 3(6):427-32. PubMed ID: 14683500
[TBL] [Abstract][Full Text] [Related]
36. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression.
Dales JP; Garcia S; Carpentier S; Andrac L; Ramuz O; Lavaut MN; Allasia C; Bonnier P; Charpin C
Hum Pathol; 2004 Feb; 35(2):176-83. PubMed ID: 14991534
[TBL] [Abstract][Full Text] [Related]
37. In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis.
Yang Y; Zhang Y; Hong H; Liu G; Leigh BR; Cai W
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2066-76. PubMed ID: 21814852
[TBL] [Abstract][Full Text] [Related]
38. Various immunostaining patterns of CD31, CD34 and endoglin and their relationship with lymph node metastasis in oral squamous cell carcinomas.
Nagatsuka H; Hibi K; Gunduz M; Tsujigiwa H; Tamamura R; Sugahara T; Sasaki A; Nagai N
J Oral Pathol Med; 2005 Feb; 34(2):70-6. PubMed ID: 15641985
[TBL] [Abstract][Full Text] [Related]
39. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(4A):2701-10. PubMed ID: 9703932
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
